Key result
ProANP 31-67 was the most sensitive marker for discriminating NYHA Class I heart failure from healthy individuals, achieving 100% sensitivity (P=0.01).
Why the study?
Does proANP 31-67 or other plasma markers accurately differentiate early congestive heart failure from healthy individuals?
Cross-Sectional (n=50)
Does proANP 31-67 or other plasma markers accurately differentiate early congestive heart failure from healthy individuals?
p-value: p=0.01
ProANP 31-67 is a highly sensitive biomarker for discriminating early (NYHA Class I) congestive heart failure from healthy individuals, outperforming ANP, BNP, and NT-proBNP.
No takes yet. Share an insight, caveat, or question.
ProANP 31-67 merits prospective validation for early HF detection; leaves open clinical utility versus existing markers.
Daggubati et al. (1997) conducted a cross-sectional in Congestive heart failure (CHF) (n=50). Plasma biomarker evaluation vs. Healthy individuals was evaluated on Sensitivity in differentiating Class I CHF subjects from healthy subjects (p=0.01). ProANP 31-67 was the most sensitive marker for discriminating NYHA Class I heart failure from healthy individuals, achieving 100% sensitivity (P=0.01).